Related Experiment Videos
New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis
1Department of Rheumatology, Leiden University Hospital, The Netherlands. F.C.Breedveld@rheumatology.medfac.leidenuniv.nl
Abstract:
Continued research towards new and better tolerated therapies to attenuate the inflammation and pain associated with rheumatoid arthritis and to halt the progression of erosive joint damage has led to the development of anticytokine strategies. Of these therapies, the most promising appear to be those targeted towards blocking the effects of TNF-alpha. Trials with etanercept, which showed significant, rapid and sustained reductions in disease activity, have produced particularly encouraging results.
Insights
New therapies targeting tumor necrosis factor-alpha (TNF-alpha) show promise for rheumatoid arthritis. Etanercept demonstrated significant reductions in disease activity, offering hope for better treatment outcomes.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) involves inflammation and joint damage.
- Current treatments aim to reduce inflammation and halt disease progression.
- Anticytokine therapies represent a novel treatment strategy for RA.
Purpose of the Study:
- To evaluate the efficacy of anticytokine strategies in treating rheumatoid arthritis.
- To assess the potential of blocking tumor necrosis factor-alpha (TNF-alpha) for RA management.
Main Methods:
- Focus on therapies targeting TNF-alpha.
- Clinical trials involving etanercept were reviewed.
Main Results:
- Etanercept demonstrated significant reductions in RA disease activity.
- The observed reductions in disease activity were rapid and sustained.
- Etanercept showed encouraging results in clinical trials.
Conclusions:
- Targeting TNF-alpha is a promising therapeutic approach for rheumatoid arthritis.
- Etanercept is an effective treatment option for reducing RA disease activity.